traveler1116/iStock Unreleased via Getty Images Listen below or on the go on Apple Podcasts and Spotify Berkshire Hathaway (BRK.B) takes new stakes in UnitedHealth (UNH), Nucor (NUE); pares back on Apple (AAPL). (00:22) Intel (INTC) spikes on speculation US considers taking stake in chip company: report. (01:22) Airbnb (ABNB) launches more flexible payment options with Reserve Now, Pay Later. (03:12) This is an abridged transcript. United Health is on the move this morning after 13F filings were disc ...

Core Insights - The data breach at UnitedHealth Group's tech unit, Change Healthcare, affected approximately 192.7 million individuals, making it the largest data breach in the U.S. healthcare industry to date [1][3][4] Group 1: Data Breach Details - The initial estimate of individuals impacted was 190 million, which was later revised to 192.7 million [2] - The breach was caused by the "Blackcat" ransomware group, leading to significant disruptions in claims processing across the nation [3] - Vulnerable information included health insurance member IDs, patient diagnoses, treatment information, social security numbers, and billing codes [4] Group 2: Financial Impact - Following the breach, Change Healthcare had to process $14 billion in backlogged healthcare claims after a month of service restoration efforts [4] - The cyberattack was noted to potentially reduce UnitedHealth Group's profit by $1.6 billion in 2024 [6] Group 3: Security Vulnerabilities - The hackers accessed the system through a Citrix portal that lacked multi-factor authentication, allowing them to move laterally within the systems [5][6] - The breach was disclosed in February, with the attack occurring on February 12, when compromised credentials were used for remote access [5]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against UnitedHealth Group Incorporated due to a class action complaint alleging breaches of fiduciary duties by the board of directors during the specified class period [1][4]. Company Overview - UnitedHealth is a leading American multinational health insurance and services company, consisting of two main segments: Optum and UnitedHealthcare. UnitedHealthcare is the largest insurance provider in the U.S., while Optum offers healthcare-related services such as software solutions and data analytics [2]. Acquisition and Legal Challenges - On January 6, 2021, UnitedHealth announced its agreement to acquire Change Healthcare, a healthcare technology company, to enhance its Optum business. The U.S. Department of Justice filed a lawsuit on February 24, 2022, challenging this acquisition on antitrust grounds, but the court ultimately allowed the deal to proceed, citing UnitedHealth's firewall policy [3]. Allegations of Misrepresentation - The class action complaint claims that UnitedHealth misled investors by assuring them of robust firewall processes to prevent the sharing of sensitive customer information between UnitedHealthcare and Optum. These misrepresentations allegedly led to inflated stock prices during the class period [4]. Impact of DOJ Investigation - The truth regarding the potential anti-competitive behavior emerged on February 27, 2024, when it was reported that the DOJ had reopened its investigation into UnitedHealth. Following this news, UnitedHealth's stock price fell by $27 per share, resulting in a loss of nearly $25 billion in shareholder value [5].

Core Insights - Berkshire Hathaway, led by Warren Buffett, has acquired 5 million shares in UnitedHealth Group, resulting in a 7% increase in the health insurer's stock during extended trading [1][3][5] - This investment marks a return for Buffett, who previously held approximately 1.18 million shares from 2006 to 2009 before selling his entire stake in 2010 [1][3] Company Challenges - UnitedHealth is currently facing significant challenges, including soaring medical costs, ongoing federal investigations, the aftermath of a top executive's murder, and a cyberattack that occurred last year [2][5] - The company has issued a new profit forecast that is considerably lower, anticipating billions in additional costs in the upcoming quarters [2] Stock Performance - Despite the recent investment news, UnitedHealth's shares have declined by 46% so far this year [5]

Core Insights - CVS Health has committed to investing $20 billion in technology over the next decade to tackle interoperability challenges in the U.S. healthcare system [1][8] - The company has joined over 60 healthcare and technology firms in supporting the CMS Health Tech Ecosystem initiative, aiming to transform healthcare through collaboration between the private sector and government [2][8] - Aetna, a CVS subsidiary, launched Aetna Care Paths, a digital offering that provides members with tailored care recommendations and clear information about procedures and benefits [3][8] Technology and Innovation - Aetna's new technology upgrades include personalized cost tracking tools, improved identification of providers accepting new patients, and AI solutions for matching digitally submitted claims [4] - UnitedHealth Group is advancing digital healthcare with a thousand AI applications across its insurance, health delivery, and pharmacy units [5] - Walmart is leveraging AI and immersive technologies to create hyper-personalized shopping experiences [6] Financial Performance - CVS Health shares have increased by 46.8% year-to-date, contrasting with a 4% decline in the industry [7] - The company's forward 12-month price-to-sales ratio is 0.21, lower than the industry average of 0.39, indicating potential value [9] - Analyst estimates for CVS's earnings in 2025 and 2026 show a bullish trend, with current estimates at 6.32 for 2025 and 7.14 for 2026 [10][11]

Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of providing misleading statements regarding its enrollment and morbidity rates, which led to a significant decline in its stock price after the company withdrew its 2025 guidance [3][4]. Group 1: Allegations and Impact - The class period for the lawsuit is from December 12, 2024, to June 30, 2025 [3]. - The complaint alleges that Centene's management made overwhelmingly positive statements while concealing material adverse facts about the company's performance [3]. - Following the withdrawal of the 2025 guidance, Centene's stock price plummeted from $56.65 per share on July 1, 2025, to $33.78 per share on July 2, 2025, marking a decline of 40.4% [3]. Group 2: Financial Adjustments - Centene's preliminary analysis indicated that its overall market growth across 22 states, representing 72% of its marketplace membership, was lower than expected [3]. - The company adjusted its previously issued guidance to approximately $1.8 billion, with an adjusted diluted EPS of $2.75 [3]. Group 3: Next Steps for Shareholders - Shareholders who purchased shares during the class period are encouraged to register for the class action by September 8, 2025 [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [4].

Group 1 - A New York state man, Shane Daley, was arrested for allegedly leaving threatening voicemails for Paulette Thompson, the widow of UnitedHealthcare CEO Brian Thompson, following his murder [1][5] - The voicemails contained profanity and threats, expressing anger towards the healthcare industry and accusing Brian Thompson of exploiting poor Americans [2][5] - Brian Thompson was killed on December 4, 2023, as he was about to attend an investor conference, and Luigi Mangione has been charged with his murder [3][5] Group 2 - The FBI linked Daley to the threatening messages through his personal cellphone number, which was recorded during the calls to Paulette's work line [6] - Daley initially denied making the threatening calls when confronted by law enforcement, but his voice was recognized by an FBI agent [7]

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Centene Corporation (NYSE: CNC) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Centene, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/centene-corporation-class-action-lawsuit. Investors have until September 8, 2025, to ask the ...

Core Viewpoint - Humana Inc. and DrFirst have launched a program aimed at improving medication therapy for patients with chronic conditions, particularly focusing on increasing statin therapy usage among eligible Medicare patients [1][2]. Group 1: Program Details - The program is designed to close care gaps for patients with chronic health conditions such as diabetes and cardiovascular disease [1]. - It utilizes the DrFirst prescription orchestration platform to facilitate timely prescription recommendations for high-risk patients, allowing healthcare providers to easily approve or decline these recommendations [2][3]. - The initiative aligns with quality metrics set by the Centers for Medicare & Medicaid Services (CMS) [1]. Group 2: Technology and Collaboration - The DrFirst platform enhances real-time interoperability among healthcare stakeholders, including providers, pharmacies, and payers, to improve patient outcomes [3][4]. - This partnership builds on a decade of collaboration between Humana and DrFirst, which includes the introduction of the first real-time prescription benefit tool in 2015 [5]. Group 3: Company Backgrounds - Humana Inc. focuses on health and well-being, providing services to various demographics, including Medicare and Medicaid recipients [6]. - DrFirst has been a pioneer in healthcare IT for 25 years, offering intelligent medication management solutions that enhance prescription access and adherence [7].

Group 1 - A class action has been filed against Centene Corporation on behalf of investors who acquired its securities between December 12, 2024, and June 30, 2025 [1] - Allegations state that Centene misled investors about its business prospects, creating a false impression of reliable revenue outlook and growth while actual enrollment rates and morbidity were lower than expected [2] - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that market growth across 22 states was lower than anticipated, leading to a reduction in guidance to approximately $1.8 billion and an adjusted diluted EPS of $2.75 [3] Group 2 - Following the announcement on July 1, 2025, Centene's stock price dropped from $56.65 to $44.78 per share, a decline of over 40% [3] - Shareholders are encouraged to participate in the class action, with options to serve as lead plaintiff or remain an absent class member [4] - Robbins LLP has been dedicated to shareholder rights litigation since 2002, focusing on helping shareholders recover losses and improve corporate governance [5]